Introduction
Epilepsy is one of the most common neurological diseases and it affects approximately nine million people in China with an annual number of 0.4-0.6 million newly diagnosed epileptic patients. 1 Antiepileptic drugs (AEDs) are generally prescribed to control seizures in this patient population. Although more than ten newer antiepileptic drugs have been licensed for treating epilepsy in the past two decades, 2, 3 carbamazepine (CBZ) and valproate (VPA) are still considered to be the first-line treatments for patients with partial seizures, and these medications are commonly prescribed in China. This trend has occurred due to the financial burden the newly drugs place on patients's families. Additionally, some comparative trials of the newly drugs compared to CBZ or VPA indicated that the newer agents have demonstrated a similar efficacy and tolerability to the two standard AEDs. [4] [5] [6] [7] [8] [9] CBZ is a drug of choice for partial seizures (simple, complex and secondarily generalized tonic-clonic seizures) 10 and VPA is a broad-spectrum AED with a good response for both partial and generalized onsets. 7, 11 The efficacy and tolerability of these two drugs have been investigated, [12] [13] [14] yet a large sample, long-term follow-up, comparison between CBZ and VPA as an initial monotherapy in patients with newly diagnosed partial seizures has not been performed for Chinese population. One way to assess the longterm performance of AEDs in daily clinical practice is to evaluate the retention rates. Compared with the other outcomes for estimating AEDs, such as the reduction of seizures, or the time to first seizure onset, the retention rate is more composite, 15, 16 and was recommended by the International League Against Epilepsy (ILAE). 17 In many previous studies that evaluated retention rates, the follow-up periods were rarely more than 6 years, however, for measuring important clinical outcomes of long-term seizure control, 18 a long follow-up period is necessary. Therefore, we designed this study to compare the retention rates between CBZ and VPA over a ten year follow-up period to provide more useful information for the clinical practice. To our knowledge this is the first study that compares the long-term retention rates between CBZ and VPA as an initial monotherapy in Chinese patients.
Methods

Patients and procedures
This study was approved by the Medical Ethics Committee at Chongqing Medical University. A total of 584 patients with newly diagnosed partial seizures, who were initially prescribed with CBZ or VPA during a period from September 1996 to January 2000, were identified through an electronic record search. The inclusion criteria included the following: (1) patients who were definitively diagnosed with partial seizures who never received AED(s). The seizure types and the types of epilepsy were defined according to the International League Against Epilepsy (ILAE) 19 ; (2) patients without contraindications for CBZ or VPA treatment; (3) patients who had at least one seizure onset within half a year before therapy. The exclusion criteria included the following: (1) patients with progressive central neurological diseases; (2) patients with clinically significant organic diseases before treatment, such as abnormal liver function, abnormal kidney function, abnormal haematological system function, abnormal endocrine system function, or heart diseases; (3) patients with acute symptomatic seizures; (4) patients with a history of psychiatric problems; (5) patients who were definitively diagnosed with epilepsy syndromes. The definition of an epilepsy syndrome was according to the ILAE. 20 The baseline demographic and follow-up data, biomedical testing records, electroencephalogram (EEG) and neuroimaging information including computer tomography (CT) and magnetic resonance imaging (MRI) for each patient were collected in case record forms in detail. The patients registration information contained gender, weight, age of first seizure onset, course of epilepsy, frequency of seizure before treatment, history of learning disabilities or developmental delay, history of febrile seizure, history of epilepsy in a first degree family members, and the underlying aetiology of the seizures. Blood routine, urine routine, liver function, kidney function and electrocardiogram (ECG) were examined. EEG and neuroimaging were also performed during the first visit. Clinicians were asked to classify the types of seizure onsets (simple partial onset, complex partial onset, or secondary generalized onset) according to ILAE guidelines, as quickly as possible. During the follow-up period, medical diaries were recorded in detail, which included the type of seizures, the occurrence of seizures, simultaneous phenomena, adverse events, and hospital admissions. For adverse events, clinicians were asked to identify whether the events were clinically significant. The patients were required to return for a follow-up visit at the second week, the first month, the third month, the sixth month, and successive half-year intervals from the date of initial treatment. The diaries were brought to the clinicians at each visit. If clinically necessary, more visits were completed. Blood routine test, serum drug concentration test, liver and kidney function tests, ECG and EEG recording were performed based on the requirement of clinical practice. If the patients did not visit the clinicians regularly, follow-up was obtained through a telephone interview with a specific clinician. If the contact with the patient was lost for more than one year, the patient was defined as a follow-up loss.
The drug dosage and titration were used by the clinicians in their daily practices. In general, the starting dosage of CBZ for children was five milligrams per kilogram per day ( The medications could be adjusted at the clinicians' discretions. The strategy of titration was performed as follows: an AED was given with an initial small dosage and the dosage was slowly escalated over time; the dosage was increased or decreased depending on the balance between efficacy and adverse events.
Evaluations and assessments
The end point of this study was the time to treatment discontinuance. The reasons for discontinuance included: adverse effects (AEs), lack of efficacy (LE), follow-up loss, poor compliance, and clinical controls. A patient who had poor compliance with a clinician's prescription was defined as a patient who discontinued CBZ or VPA by their own volition. A patient who was seizure free for five consecutive year with a normal neurologic examination, intelligence quotient (IQ) and EEG results, were considered for discontinuation of AEDs by a clinician. 21 When CBZ or VPA was to be discontinued by clinician's recommendation, the drug was eliminated from the patient's regimen, by tapering the dose slowly over 6 months. During this time period, if recurrence of seizures was observed, the prior dosage was reinstituted at the previously effective level; if no recurrence, the patient was considered to be clinically controlled. Efficacy was evaluated by seizure freedom rates and five-year remission rates. Seizure freedom was defined as no seizure onset for at least twelve months at end of each year. A five-year remission was defined as no seizure onset for at least five consecutive years. The twelve-month seizure frequency before AED treatment was considered to be the baseline. If the course of epilepsy was less than twelve months, the frequency of baseline was assessed using the formula below:
Frequency ðtimes=yearÞ ¼ times of seizures course of epilepsy ðdaysÞ Â 365 ðdaysÞ:
Statistical analysis
Cox proportional hazard model (95% confidence interval) was established to analyze the risk factors of AED discontinuations (which included factors such as: gender, age of first seizure onset, seizure duration before treatment, frequency of baseline, type of seizure, and choice of AED). Intention-to-treat (ITT) analysis was used to analyze the seizure freedom rates, the five-year remission rates, and the retention rates. Kaplan-Meier survival analysis was used to estimate the cumulative probability of retention; log-rank test was used to analyze the comparison between the retention curve of CBZ and VPA. The differences in the Kaplan-Meier curves between the two groups were estimated by 95% confidence intervals. The reasons for censoring in Kaplan-Meier analysis were defined as follows: during the medication period, patients suffered tumours, but the tumours were not caused by AED treatment; patients who died, but the death had no association with AED treatment; patients who had plans to receive operations, but the operations had no association with antiepileptic treatment; patients who had the plans of pregnancy; patients who still continued AED treatment at the end of this study. Chi-square test and Fisher's probabilistic method were used to analyze the data between both drugs in terms of seizure remission and reason for discontinuation. A t-test was performed for independent twosample data. The data were expressed as mean AE standard deviation (SD). All of the statistical analyses were performed with SPSS v17.0 software for windows.
Results
Basic information
A total of 584 patients were enrolled in our study: 252 received CBZ and 332 received VPA. Table 1 lists the basic information of the patients. The mean age was 22.6 AE 12.2 years for CBZ and 24.3 AE 14.7 years for VPA. The age of first seizure onset was 20.9 AE 11.8 years for CBZ and 22.4 AE 14.6 years for VPA. The mean duration before treatment was 1.6 AE 3.7 years and 1.8 AE 3.6 years respectively. The two groups were balanced for clinical and demographic factors.
Retention rate
One year after the treatment began, for CBZ: 196 patients (77.8%) continued, with the annual discontinuation rate of 8.6% (range 3.6-22.2%); for VPA: 253 (76.2%) patients continued, with the annual discontinuation rate of 9.2% (range 2.1-23.8%). The calculated retention rate estimated by Kaplan-Meier survival analysis showed a similar result. There was no significant difference in the actual retention rate between the CBZ and VPA groups, which were investigated at specific time-periods (Table 2) . Log rank testing for the survival curves in Fig. 1 , also showed no significant difference between the two AEDs (p = 0.074). A Cox proportional hazard model revealed that gender (p = 0.181), age of first seizure onset (p = 0.759), seizure duration before treatment (p = 0.128), frequency of baseline (p = 0.867), type of seizure (complex: simple, p = 0.207; secondary generalized: simple, p = 0.415), and choice of AED (p = 0.09) were not risk factors for treatment discontinuations in our study.
The causes for CBZ and VPA discontinuation are shown in Table  3 . Clinical control that led to drug discontinuation represented 15.9% of CBZ treated patients compared to 7.5% of VPA patients (p = 0.001). During the time period from the first six months to two years after the initial treatment, LE leading to drug discontinuation occurred for 10.7% of CBZ patients compared to 4.5% of VPA patients (p = 0.004), AEs that led to drug discontinuation represented 2.4% of CBZ patients compared to 6.3% of VPA patients (p = 0.025). For CBZ, during the first fifteen days of treatment, follow-up loss was the most important cause for drug discontinuation. Afterwards, AEs were the major cause between fifteen days to six months after initial treatment. Then LE was the most frequent reason from six months to two years. After six years, clinical control became the major cause for medication discontinuation. For VPA, during the first month, follow-up loss was the most important cause for drug discontinuation. Afterwards LE and poor compliance were the two most important causes during the one-to three-month period after initial treatment. Then AEs were the most frequent reason for discontinuation from three months to six months. From six months to one year, LE was the most cited reason again. From one to two years, AEs and follow-up loss were the two most frequent causes for discontinuation. After six years, clinical control was the major cause for medication discontinuation as well as CBZ. Table 4 shows the patients who were completely seizure free for at least one year between each assessment point. Seizure freedom rates for the intervals T2-3 years and T5-6 years were significantly higher in the CBZ group (p = 0.015 and 0.021, respectively). For other intervals, no significant difference was founded between the CBZ group and the VPA group; (the p values ranged from 0.051 to 0.891).
Efficacy
The five-year remission rate was higher in the CBZ group (33.3%) than that in the VPA group (23.2%) (p value was 0.006 (Table 5) ). In the simple partial seizure subgroup and the secondary generalized seizure subgroup, the patients treated with CBZ were more likely to achieve five-year remission than the patients treated with VPA (61.5%:16.7%, p = 0.021 and 32.0%:23.9%, p = 0.043, respectively). In the complex partial seizure subgroup, there was no significant difference between the two drugs (28.6%:16.7%, p = 0.61). Table 6 shows all AEs leading to drug discontinuation between each assessment point. The four most common AEs for CBZ were skin rash (in 3.6% patients), abnormalities in liver function (2.4%), dizziness (1.2%), and cardiopalmus (1.2%). For VPA, abnormalities in liver function (1.8%), lethargy (1.2%), dizziness (1.2%), and weight gain (1.2%) were the four most common AEs. In the CBZ group, more than 70% of AEs that led to discontinuation appeared within six months after initial treatment, compared to a period of three months to two years in the VPA group.
Adverse effects
Discussion
China has the largest population in the world and the most epileptic patients as well. 1 For economic reasons, CBZ and VPA are far more commonly prescribed for Chinese patients with partial seizures than the newer licensed agents in present China. Data on the efficacy and tolerability of these two AEDs in previous studies 7, [22] [23] [24] were almost based on Euramerican and Japanese populations. To account for the differences in genetic, environmental factors, and pharmacokinetic processes among different populations, the previous reports may be not entirely suitable for Chinese patients. 25 So adding the results from Chinese clinical trials will be important to antiepileptic practices of the world. Epilepsy is a chronic neurological disorder, and treatment requires a long period of time. To assess the long-term performance of AEDs comprehensively, a substantial period of time for follow-up is required and a composite indicator must be used. Long-term retention rate meets these two requirements. [15] [16] [17] In our study, there were 584 patients who were observed during a follow-up period of up to 10 years. To our knowledge, this is the longest follow-up period from a study conducted in China. The large number of patients included in this study, the long-term follow-up period increased the possibility of finding clinically important differences between CBZ and VPA. Meanwhile, to achieve the goal of contributing to everyday clinical practice, the entry criteria of this study were as inclusive as possible and clinicians were asked to treat patients based on their routine clinical practice. Retention time on an AED was defined as the time from initial monotherapy to withdrawal of AED treatment or addition of another agent. Retention time is customarily considered to be a composite indicator for evaluating drug efficacy and tolerability. However some non-drug-related events such as follow-up loss and poor compliance may also lead to treatment failure. 26 These possibilities were considered to be discontinuation causes in our Kaplan-Meier survival analysis. The discontinuation of AED treatment is considered to be a valuable option in the patients who had been seizure free for five years or longer. 21 Based on these findings, the decisions of terminating AED treatment were made for the patients who were well controlled for at least five consecutive years and had normal neurologic examinations, intelligence quotient (IQ) and EEG results as well as no recurrence of seizures during the decrement period. Once the patients had successfully terminated CBZ or VPA, they would be considered to be clinically controlled. Some patients relapsed after the medication was withdrawn, and the subsequent research focus on the factors associated with risk of seizure relapse in Chinese epileptic patients was performed in our centre with specific methodological design, but the results have not been included in this article. Previously, for time to treatment discontinuation, a metaanalysis of randomized controlled trials showed that there was ''no reliable evidence to distinguish CBZ and VPA for partial-onset seizures''. 7 This finding was similar to ours. Yet in these studies the retention rates of CBZ and VPA that were reported that at the oneyear time point were around 60-70%, and decreased to around 20-30% after four years of follow-up. 7, 27 The differences between the current study and previous reports may be due to: (1) the Chinese population selected in our study had better response for CBZ and VPA than other populations recruited in the early investigations; (2) the patients were only newly diagnosed in our study, but in previous there were more patients that may have turned out to be refractory before the investigations started. Interestingly, in present study, the patients treated with CBZ were more likely to discontinue medication for LE, but were less likely to discontinue treatment for AEs than those treated with VPA. This difference only occurred in the time period between the first six months to two years after the initial treatment. This finding is an important since it showed that clinicians should pay more attention to efficacy for patients treated with CBZ, and more attention to tolerability for patients treated with VPA during this time period. The main objective of epilepsy treatment is to control seizures, since seizure onset has the greatest impact on quality of life. 28 Thus we chose to examine seizure freedom rates and five-year remission rates to measure efficacy. It is notable that the seizure freedom rates of both CBZ and VPA did not decrease gradually but decreased apparently every two to three years followed by a relatively stable phase. Comparable percentages of patients achieved seizure freedom with both drugs before two years. After this period of time, more patients on CBZ achieved seizure freedom for at least one additional year (although not all of these differences were statistically significant). Based on our results the seizure freedom rates of VPA decreased faster than those of CBZ, and there is a twoto three-year stable-decreased-stable cycle for seizure freedom rates for both drugs. Generally, the effective rate of drug treatment decreases over time. However, the stable-decreased-stable cycle was observed for the first time in Chinese epileptic patients, and our results could contribute to clinicians' daily practices. The percentage of patients who achieved five-year remission was higher in CBZ-treated group than in VPA-treated group. This difference occurred due to the fact that CBZ had a better seizure freedom outcome than VPA. In previous randomized controlled trials comparing CBZ and VPA, evidence was provided that CBZtreated patients was better on the outcomes of time to first seizure and time to twelve-month remission. 10, 23, 24 Our findings showed that CBZ was also better than VPA for the long-term seizure control in Chinese patients with simple partial onset and secondary generalized onset. In this study, 25.9% of patients treated with CBZ and 33.3% of patients treated with VPA reported adverse events. 11.1% and 10.2% of the CBZ and VPA patients discontinued medication due to AEs, respectively. No death or life-threatening AEs appeared during follow-up. The percentage of patients who discontinued treatment due to AEs for either drug was comparable, and discontinuations occurred quite early in the course of medication, usually within one year of initial treatment. Our findings showed that if the medication is initially well tolerated, the long-term tolerability of CBZ and VPA for Chinese epileptic patients is good. Rash was commonly considered to be a serious AE in previous studies, and the discontinuations due to rashes largely occurred within the first two to eight weeks after drug initialization. 29 In our study, skin rash complaints were the most common adverse event for discontinuation in the CBZ group. In contrast to only a few patients discontinued treatment for skin rash in the VPA group. Abnormalities in liver function were reported for both AEDs, liver problems were the most common cause for discontinuation in the VPA group, although the percentage of patients with abnormalities in liver function was higher in the CBZ group. Follow-up loss was the most common cause of discontinuation of treatment in our study. Although clinicians informed the patients that epilepsy is a chronic disease and requires long-term treatment, approximately 50% of follow-up loss events occurred within the first two weeks after initial treatment. Compared with the non-loss cohort, the percentage of patients living far from our centre in the follow-up loss cohort was much higher. Long distance travel incurs a higher cost of time and traveling expenses for each visit, and this higher cost likely aggravated the economic and mental burden of the patients, especially since some of those patients have told the clinicians that they were afraid of being fired for frequent absences at work. Limited forms of communication may be the other cause for patient follow-up loss. We only recorded the patient's telephone number and address, since these two kinds of communication are the most common ways to communicate with patients in China. For decreasing follow-up loss in the future, collecting more contact information could be useful.
Conclusion
Our study suggested that there is no significant difference in retention rates between CBZ and VPA as an initial monotherapy for Chinese patients with partial seizures. Lack of efficacy, adverse effects, follow-up loss, poor compliance and clinical control were the causes leading to discontinuations of treatment. Patients taking CBZ were more likely to discontinue treatment because of clinical control. Additionally, between the first six months to two years, the patients treated with CBZ were more likely to discontinue treatment for LE, but they were less likely to discontinue treatment for AEs than patients treated with VPA. The patients with simple partial seizure onset and secondary generalized onset treated with CBZ were more likely to achieve long-term remission than those treated with VPA. The most common intolerable AE for CBZ was rash and the most common AE for VPA was abnormalities in liver function.
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